Drug intelligence / Profile preview

RPTR-3-001

Development stage: Preclinical
Lead developer: Repertoire Immune Medicines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RPTR-3-001 is an investigational, preclinical-stage mRNA-based tolerizing vaccine being developed by Repertoire Immune Medicines for the treatment of Type 1 Diabetes. Discovered using Repertoire's proprietary DECODE platform, which maps the immune synapse to identify disease-driving T-cell receptor (TCR)-epitope pairs, RPTR-3-001 is designed to restore immune tolerance and homeostasis. By delivering specific autoantigens in a non-inflammatory mRNA format, the therapy aims to reprogram autoreactive T cells and expand regulatory T cells (Tregs) to prevent the autoimmune destruction of pancreatic beta cells without causing systemic immunosuppression.

Beyond the preview

Go deeper on RPTR-3-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPTR-3-001.

Explore the full profile